If ultimately approved, the drug, aducanumab, made by Biogen, would be the first new Alzheimer’s treatment in nearly two decades. Some evidence suggests it slows, but does not stop, cognitive decline.
Published: November 6, 2020 at 11:00AM
from NYT Health https://ift.tt/3jZ7hgp